Adaptimmune Therapeutics plc (ADAP)’s Financial Results Comparing With Kala Pharmaceuticals Inc. (NASDAQ:KALA)

Adaptimmune Therapeutics plc (NASDAQ:ADAP) and Kala Pharmaceuticals Inc. (NASDAQ:KALA), are influenced by contrast since they are both players in the Biotechnology. These factors are particularly influence the risk, analyst recommendations, profitability, institutional ownership, dividends, earnings and valuation of the two firms.

Valuation & Earnings

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Adaptimmune Therapeutics plc 62.30M 8.09 86.60M -0.93 0.00
Kala Pharmaceuticals Inc. N/A 0.00 52.81M -3.30 0.00

Demonstrates Adaptimmune Therapeutics plc and Kala Pharmaceuticals Inc. earnings per share, gross revenue and valuation.

Profitability

Table 2 represents Adaptimmune Therapeutics plc (NASDAQ:ADAP) and Kala Pharmaceuticals Inc. (NASDAQ:KALA)’s return on equity, net margins and return on assets.

Net Margins Return on Equity Return on Assets
Adaptimmune Therapeutics plc -139.00% -41.5% -33%
Kala Pharmaceuticals Inc. 0.00% -72.1% -52.7%

Liquidity

The current Quick Ratio of Adaptimmune Therapeutics plc is 8.8 while its Current Ratio is 8.8. Meanwhile, Kala Pharmaceuticals Inc. has a Current Ratio of 6.3 while its Quick Ratio is 6.3. Adaptimmune Therapeutics plc is better positioned to pay off its short-term and long-term debts than Kala Pharmaceuticals Inc.

Analyst Ratings

The table shown features the ratings and recommendations for Adaptimmune Therapeutics plc and Kala Pharmaceuticals Inc.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Adaptimmune Therapeutics plc 0 0 1 3.00
Kala Pharmaceuticals Inc. 0 0 0 0.00

The upside potential is 231.95% for Adaptimmune Therapeutics plc with consensus target price of $16.

Insider & Institutional Ownership

Institutional investors held 63% of Adaptimmune Therapeutics plc shares and 52.1% of Kala Pharmaceuticals Inc. shares. Adaptimmune Therapeutics plc’s share held by insiders are 0.23%. Competitively, Kala Pharmaceuticals Inc. has 3.2% of it’s share held by insiders.

Performance

Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Adaptimmune Therapeutics plc -4.71% -11.73% -45.95% -52.58% -26.44% -12.13%
Kala Pharmaceuticals Inc. -8.57% -24.31% -48.89% -56.95% -69.72% -68.85%

For the past year Adaptimmune Therapeutics plc was less bearish than Kala Pharmaceuticals Inc.

Summary

On 8 of the 10 factors Adaptimmune Therapeutics plc beats Kala Pharmaceuticals Inc.

Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on the provision of cancer immunotherapy products based on its proprietary SPEAR T-cell platform. Its platform enables to identify cancer targets; find and genetically engineer T-cell receptors (TCR); and produce TCR therapeutic candidates for administration to patients. The companyÂ’s lead program includes NY-ESO-1 and LAGE-1a cancer antigens, which are in Phase I/II clinical trials for patients with solid tumors, as well as hematological cancer types, including synovial sarcoma, multiple myeloma, non-small cell lung cancer (NSCLC), and ovarian cancer; and pilot trial for myxoid round cell liposarcoma. It is also developing MAGE A-10 peptide that is in Phase I/II clinical trials to treat urothelial (bladder), melanoma, and head and neck cancers, as well as NSCLC; AFP SPEAR T-cell therapeutic candidate that has completed preclinical testing for targeting a peptide associated with hepatocellular carcinoma; and MAGE-A4 to treat urothelial (bladder), melanoma, head and neck, esophageal and gastric, and ovarian cancer, as well as NSCLC. It has a strategic collaboration and licensing agreement with GlaxoSmithKline for the development and commercialization of the NY-ESO SPEAR T-cell program; and strategic alliance with MD Anderson Cancer Center for the development of T-cell therapies for various cancers. The company also has a clinical trial collaboration agreement with Merck & Co., Inc. for the assessment of NY-ESO SPEAR T-cell in combination with anti-programmed death-1 inhibitor in patients with multiple myeloma; and a research, collaboration, and license agreement with Universal Cells, Inc. to gene editing and HLA-engineering technology, as well as a collaboration agreement with Bellicum Pharmaceutical Inc. to evaluate, develop, and commercialize next generation T-cell therapies. Adaptimmune Therapeutics plc was founded in 2014 and is headquartered in Abingdon, the United Kingdom.

Kala Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies using its proprietary nanoparticle-based Mucus Penetrating Particles technology. The companyÂ’s product candidates include KPI-121 1.0%, which has completed Phase 3 clinical trials for the treatment of inflammation and pain following ocular surgery; and KPI-121 0.25% that is in Phase 3 clinical trials for the temporary relief of the signs and symptoms of dry eye disease. It also develops KPI-285, a receptor kinase inhibitor, which is in preclinical studies for the treatment of various retinal diseases. The company was formerly known as Hanes Newco, Inc. and changed its name to Kala Pharmaceuticals, Inc. in December 2009. Kala Pharmaceuticals, Inc. was founded in 2009 and is headquartered in Waltham, Massachusetts.